Alpha-1-proteinase inhibitor is a purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency. Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
- Mechanism
- Curator reviewed
Alpha-1 proteinase inhibitor is a serine protease inhibitor (Serpin). Its primary mechanism is inhibiting the action of the serine protease called elastase (also plasmin and thrombin) in the lungs. The reactive center loop (RCL) of alpha-1 proteinase inhibitor extends out from the body of the protein and directs binding to the target protease. The protease cleaves the serpin at the reactive site, establishing a covalent linkage between the carboxyl group of the serpin reactive site and the serine hydroxyl of the protease. The resulting inactive serpin-protease complex is highly stable.
- Primary indication
- For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.Curator reviewed · 2 structured indications
- Formula / weight
- C2001H3130N514O601S10 · 44324.5 Da
- First approval
- Canada, 2012 · United States, 1987 · European Union, 2016
- Also known as
- .Alpha.-1 protease inhibitor · .Alpha.1-proteinase inhibitor human · 122320-05-2 · Alfa 1-proteinase inhibitor (human) · Alfa1 antitrypsin
- Code names
- 232-924-7 · ALP · HUSI-1 · SLPI
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Alpha-1-proteinase inhibitor, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account